Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

authors michael-d-brown

New Medication has Implications to avoid Would-be Chronic Diseases

PharmD Live

APRIL 20, 2022

In general, Medicare prescription drug plans (Part D) do not cover this drug. About the author. Rubino D, Abrahamsson N, Davies M, et al. Kushner, Steve Marso, Jorge Plutzky, Kirstine Brown-Frandsen, Marianne O.L. Be sure patients contact their specific plan to verify coverage information. Xenical (Orlistat) $823.45

Hospitals

Hospitals FDA

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

The FDA Law Blog

NOVEMBER 1, 2023

Javitt & Michael D. Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). Mullen & Gail H. Shumsky & Philip Won & Adrienne R.

FDA

FDA Hospitals Immunization

New Medication has Implications to avoid Would-be Chronic Diseases

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

Stay Connected